

Essential Data To process the referral, please provide the following minimum information:

- Patient demographic information and any additional relevant clinical documentation (labs and tests)
- Copy of insurance card (front and back)
- History and physical documentation (including documentation of infection history and diagnosis, recent hospitalizations)
- Recent medication list, IV access information, and home health agency if applicable
- Currently received and/or prior filed therapies along with lengths of treatment and/or reason for discontinuation

Patient Demographics

Last Name:		First Name:		SSN:
Date of Birth:	Sex:	Height (cm):	Weight (kg):	
Allergies:				
Address:				
City:		State:	Zip:	
Home Phone:		Mobile Phone:		
Emergency Contact Name:		Emergency Contact Phone:		
<input type="checkbox"/> Other Diagnosis/ICD-10:		<input type="checkbox"/> Other Diagnosis/ICD-10:		
If unable to find diagnosis/ICD-10 code, please refer to ICD-10-CM (cdc.gov) for reference.				

Patient Insurance Information

Primary Insurance Name:	Secondary Insurance Name:
Policy Holder Name:	Policy Holder Name:
Relation to Policy Holder:	Relation to Policy Holder:
Member ID:	Member ID:
Group ID:	Group ID:

Prescription*

Medication	Dose/Strength	Directions
<input type="checkbox"/> Ocrevus (ocrelizumab)	300mg vial	<input type="checkbox"/> INITIAL: Infuse 300mg IV on day 1 and day 15 <input type="checkbox"/> MAINTENANCE: Infuse 600mg IV once every 6 months (max duration of 1 year)
<input type="checkbox"/> Tysabri (natalizumab)	300mg vial	<input type="checkbox"/> Infuse 300mg IV every 4 weeks (max duration of 1 year)
<input type="checkbox"/> Briumvi (ublituximab)	150 mg vial	<input type="checkbox"/> INITIAL: <input type="checkbox"/> 150mg IV infusion <input type="checkbox"/> 450mg IV infusion at 2 weeks after first infusion <input type="checkbox"/> MAINTENANCE: 450mg IV every 24 weeks (max duration of 1 year)
<input type="checkbox"/> Lemtrada (alemtuzumab)	12mg vial	<input type="checkbox"/> INITIAL: <input type="checkbox"/> 12mg IV infusion for 5 consecutive days <input type="checkbox"/> 12mg IV infusion for 3 consecutive days 12 months after first infusion
<input type="checkbox"/> Vyvgart (efgartigimod alfa)	400mg vial	<input type="checkbox"/> 10mg/kg (max dose 1200mg) IV once weekly for 4 weeks (max duration of 1 year)
<input type="checkbox"/> Vygart-Hytrulo (efgartigimod alfa and hyaluronidase-QVFC)	180mg/2000units vial	<input type="checkbox"/> Administer 1,008mg/11,200 SQ weekly for 4 weeks (max duration of 1 year)
<input type="checkbox"/> Rystiggo (rozanolixizumab)	280mg vial	<input type="checkbox"/> <50kg: 420mg SQ once weekly for 6 weeks (max duration of 1 year) <input type="checkbox"/> 50kg to 100kg: 560mg SQ once weekly for 6 weeks (max duration of 1 year) <input type="checkbox"/> >100kg: 840mg SQ once weekly for 6 weeks (max duration of 1 year)
<input type="checkbox"/> Ultomiris (ravulizumab)	300mg vial 1,100mg vial	<input type="checkbox"/> INITIAL: Weight based dosing, infuse IV <input type="checkbox"/> 40kg to 59kg: 2,400mg <input type="checkbox"/> 50kg to 100kg: 2,700mg <input type="checkbox"/> >100kg: 3,000mg <input type="checkbox"/> MAINTENANCE: Weight based dosing, infuse IV 2 weeks after initial dose (max duration of 1 year) <input type="checkbox"/> 40kg to 59kg: 2,400mg IV every 8 weeks <input type="checkbox"/> 50kg to 100kg: 2,700mg IV every 8 weeks <input type="checkbox"/> >100kg: 3,000mg IV every 8 weeks <input type="checkbox"/> OTHER: _____
<input type="checkbox"/> Soliris (eculizumab)	300mg vial	<input type="checkbox"/> INITIAL: Infuse 900mg IV weekly for 4 weeks, followed by 1200mg IV for fifth dose 1 week later <input type="checkbox"/> MAINTENANCE: Infuse 1200mg IV every 2 weeks (max duration of 1 year) <input type="checkbox"/> OTHER: _____
<input type="checkbox"/> Uplizna (inebilizumab-cdon)	100mg vial	<input type="checkbox"/> INITIAL: 300mg IV followed by 300mg at 2 weeks <input type="checkbox"/> MAINTENANCE: 300mg IV starting 6 months after first infusion (max duration of 1 year)
<input type="checkbox"/> Radicava (edaravone)	30mg vial	<input type="checkbox"/> INITIAL: 60mg IV daily for 14 days followed by 14-day infusion free period <input type="checkbox"/> MAINTENANCE: 60mg IV daily for 10 days out of 14 followed by a 14-day infusion free period (max duration of 1 year)
<input type="checkbox"/> Vypeti (eptinezumab-jjmr)	100mg vial	<input type="checkbox"/> 100mg IV every 12 weeks (max duration of 1 year) <input type="checkbox"/> 300mg IV every 12 weeks (max duration of 1 year)
<input type="checkbox"/> Leqembi (lecanemab-irmb)	200mg vial 500mg vial	<input type="checkbox"/> 10mg/kg IV every 2 weeks (max duration of 1 year) MRIs at baseline, prior to 5th, 7th, and 14th infusion
<input type="checkbox"/> Aduhelm (aducanumab-avwa)	170mg 300mg	<input type="checkbox"/> INTIAL IV every 4 weeks as follows: <input type="checkbox"/> 1mg/kg infusion every 4 weeks for infusions 1 and 2 <input type="checkbox"/> 3mg/kg infusion every 4 weeks for infusions 3 and 4 <input type="checkbox"/> 6mg/kg infusion every 4 weeks for infusions 5 and 6 <input type="checkbox"/> MAINTENANCE: Starting with infusion 7, infuse 10mg/kg every 4 weeks (max duration of 1 year)

Additional Management Orders*

Hydration Protocol: <input type="checkbox"/> Per Pharmacy Protocol <input type="checkbox"/> Per Provider Protocol	Premedication Protocol <input type="checkbox"/> Per Pharmacy Protocol <input type="checkbox"/> Per Provider Protocol	Anaphylaxis Protocol: <input type="checkbox"/> Per Pharmacy Protocol <input type="checkbox"/> Per Provider Protocol
Flush Protocol: <input type="checkbox"/> Per Pharmacy Protocol <input type="checkbox"/> Per Provider Protocol	Labs Protocol: <input type="checkbox"/> Per Pharmacy Protocol <input type="checkbox"/> Per Provider Protocol	Other: _____

*Product selection permitted unless dispense as written is checked or clearly written on order form.
*Vials will be rounded to the nearest vial if appropriate unless clearly written to dispense dose as written from provider.

Notes to Pharmacy

- First Dose to be given in home
- Skilled Nursing visits as required

Referring Provider Information

Ordering Provider's Name:		
NPI:	Specialty:	
Facility Name:		
Address:		
City:	State:	Zip:
Office Phone:	Office Fax:	
Dispense as Written		
Provider Signature:	Date:	

I authorize Vital Care Infusion Services LLC and its representatives to initiate any insurance prior authorization process that is required for this prescription and for any future refills of the same prescription for the patient listed above which I order. I understand that I can revoke this designation at any time by providing written notice to Vital Care.

PRESCRIBER MUST MANUALLY SIGN - STAMP SIGNATURE, SIGNATURE BY OTHER PERSONNEL AND COMPUTER-GENERATED SIGNATURES WILL NOT BE ACCEPTED

The attached document(s) contain confidential information which may be considered to be Protected Health Information and therefore required to be maintained as private and secure under HIPAA. The documents may also contain information which is otherwise considered to be privileged under state and federal laws. This communication is for the intended recipient only. If you are not the intended recipient, or a person responsible for delivering this communication to the intended recipient, you are prohibited from viewing, copying and/or distributing the information contained herein. Unlawful disclosure of the information attached may subject you to monetary penalties and sanctions. If you have received this communication in error, you should notify the sender immediately and thereafter permanently destroy all copies of this document in its entirety. This form is not considered an order or prescription for medical services and/or supplies unless and until it is formally authorized by a healthcare provider in compliance with applicable laws and regulations.